Trial-Ready Cohorts Take Shape in Europe and U.S.
At CTAD, researchers discussed baseline data from the first 500 participants in the EPAD cohort and, finally, the start of recruitment for TRC-PAD.
NEWS
Trials of Diabetes-Related Therapies: Mainly a Bust
At CTAD, intranasal insulin trial stumbles, pioglitazone gets a postmortem, a RAGE inhibitor tries to hang on.
Fits and Starts: Trial Results from the CTAD Conference
In Barcelona, data ran the gamut from a few hopeful little hints on new treatments to mixed signals on familiar players, and failed drugs thrown on the scrap heap.
How Does The NIA-AA Framework Measure Up Against Real Data?
Researchers are applying the proposed 2018 NIA-AA diagnostic criteria to three large, standing cohorts. How did the research framework perform?
Not Just Motoneurons: Sensory Neurons Suffer Effects of ALS
Cultured sensory neurons from ALS mouse models have truncated, less-complex neurites that grow slowly compared to controls.
Is NfL the New 'N' in A/T/N Classification of Alzheimer’s?
People with a lot of neurofilament light protein in their spinal fluid are more likely to develop mild cognitive impairment in the next four years.
Amyloid PET Aids Diagnosis. But Could CSF Do Just as Well?
Large IDEAS data set establishes that PET scans are valuable in clinical practice. Other studies suggest CSF biomarker ratios perform nearly as well.
It’s Official: Tau PET Sees Tangles, and Staging Tangles Predicts Decline
Scientists at CTAD were excited about postmortem validation of tau scans and new, more sensitive tracers. Others are exploring practical applications for live imaging of tau pathology.
Virtual Exhibit Hall
Alzforum encourages users to visit the Virtual Exhibit Hall, where companies showcase their newest initiatives, products, and services. We welcome Dash Genomics, Inc. and Abcam, which join our other exhibitors — Biogen, BioLegend, NanoString Technologies, Inc., and the Jackson Laboratory.
SPOTLIGHT
Clinical Trial Roundup from CTAD
As its name implies, the Clinical Trials on Alzheimer Disease conference, held October 24–27 in Barcelona, was the place to hear the latest on investigational treatments in the pipeline. Get caught up with Pat McCaffrey’s two-part series on recent results. She’s got the goods on plasma exchange therapy, a seaweed-derived oligosaccharide from China, an antiviral, new Aβ vaccines, allopregnanolone, intranasal insulin, and more. Who were the winners and the losers?
How Does the NIA/AA Research Framework Stack Up In Real Life?
At CTAD2018, researchers described first efforts to figure out how the 2018 NIA-AA research diagnostic criteria apply to real people in real time. They report that biomarkers of amyloid, tau, and neurodegeneration predict progression to dementia fairly well; however, better cognitive tests are needed for symptomatic staging of early disease.
Join The Conversation
Professional Resources
New in last 7 days
-
Grants
- New Items: 8
- Total Items: 236
-
Jobs
- New Items: 2
- Total Items: 93
-
Conference Calendar
- New Items: 2
- Total Items: 53
- Member Directory
Latest Comments